Net Asset Value(s)

Valuation dated 2025-12-18 for LISTD PRIVTE EQTY UCITS (ISIN IE0008ZGI5C1) shows a NAV per unit of USD 34.7132 with 10,567,022 units reported. The update is a routine NAV publication for this private equity UCITS and provides the current per‑unit valuation for portfolio accounting and investor reporting; it is unlikely to drive meaningful market moves on its own.

Analysis

Market structure: The NAV print (NAV/unit = $34.7132; units 10.567M → fund NAV ≈ $367M) signals a mid‑sized listed private equity vehicle with limited daily liquidity; winners are listed PE sponsors and ETFs (BX, KKR, PSP) if secondary volumes and rate tailwinds compress discounts, losers are late‑stage public “private-like” growth names that reprice on improved access to private exits. Competitive dynamics favor large GP franchises that can monetize carry and secondaries; pricing power shifts to sponsors who can force exits when public IPO windows reopen, compressing LP discounts by 100–300 bps within 3–12 months. Cross‑asset: a 25–50 bp Fed cut and 10y fall >30–50 bps would likely tighten discounts, lift listed PE and credit spreads, reduce equity volatility (VIX -10–25%) and modestly weaken USD; opposite moves widen discounts and stress credit market funding for buyouts.

Risk assessment: Tail risks include sudden secondary market freezes, carry tax/regulatory changes, or macro shock that forces >15% NAV markdowns; operational risks include stale NAVs and gating. Immediate (days) risks: NAV reprices and liquidity gaps; short term (weeks–months): Fed signals and secondary auctions will determine discount trajectory; long term (quarters) actual exits/realizations drive realized returns. Hidden dependencies: NAV sensitivity to late‑stage valuation multiples and IPO windows (a 20% compression in exit multiples could cut NAV by ~8–15%). Catalysts: quarter‑end NAV updates, large LP redemptions, Fed decision (next 60–120 days) and any high‑profile secondary deal prints.

Trade implications: Direct plays - buy listed private equity exposure (PSP) as a proxy and equity stakes in sponsors (BX, KKR, CG) as leveraged reads on fee/distribution growth; pair trades - long PSP (or BX) vs short thematic growth (ARKK) to capture discount tightening. Options - build convexity via 6–9 month call spreads on BX/KKR and buy protective puts on PSP if funding spreads widen; allocate modestly (0.5–3% of portfolio) given liquidity. Entry/exit: act within 30 days if Fed futures price ≥25 bp cut by Mar 2026 or if secondary prints show discount narrowing >150 bps; set stop losses at 10–12% and targets 20–30% over 9–12 months.

Contrarian angles: Consensus underweights GP balance‑sheet optionality — large sponsors can accelerate distributions via stapled secondaries or IPO underwriting, unlocking value faster than models expect. The market may overprice liquidity risk versus realizable value: if secondary bids reappear, NAV discounts can snap back quickly (200–400 bps) — tradeable with small, levered positions. Historical parallels: 2016 and 2020 discount compressions post‑rate relief were swift; but unintended consequences include a surge in supply (restarts of IPO pipelines) that could temporarily depress public multiples and hurt short ARKK positions if growth re‑rates higher unexpectedly.

Key Decisions for Investors

• Establish a 2.5% long position in Invesco Global Listed Private Equity ETF (PSP) within 30 days to capture potential 20–30% re‑rating over 9–12 months if 10y yield falls >30 bps or Fed cuts ≥25 bps by Mar 2026; set stop-loss at -12% and take-profit tranche at +20% and +30%.
• Allocate 1–2% long equally to Blackstone (BX) and KKR (KKR) as leveraged plays on fee income and distribution growth; hedge tail risk by buying 6–9 month call spreads (buy ATM, sell 15–25% OTM) sized 0.5–1% notional each; target 25–35% upside in 9–12 months, stop-loss -15%.
• Implement a relative trade: long PSP (2%) / short ARK Innovation ETF (ARKK) (1.5%) for 6–12 months to capture discount compression vs thematic growth derating; unwind if PSP discount-to‑NAV narrows >200 bps or PSP NAV rises >15%.
• Reduce direct exposure to public, late‑stage ‘private‑like’ growth stocks by 25–50% within 30 days if a company has negative free cash flow and trailing 12m price/sales >10x; redeploy proceeds into listed PE (PSP) or sponsor equities (BX, KKR) as per above allocations.